Spravato Marketing for Certified Centers

The short answer

Spravato marketing is how a REMS-certified center reaches patients and referring prescribers for esketamine nasal spray. The SPRAVATO REMS sets the constraints: the drug is administered only in certified healthcare settings, the patient is monitored on site for at least two hours after each dose, and cannot drive until the next day. Approved indications are treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. Esketamine carries a boxed warning. Advertising it outside the indication is off-label promotion of a controlled substance.

new Spravato patients started per month across certified center clients — verify with Tim

Patients started monthly

share of starts arriving by prescriber referral versus search — verify

Referral versus search mix

Write the comparison page nobody else will

Ketamine infusion and Spravato are different products with different rules, and the person searching does not know that. Infusion clinics use generic ketamine off label, mostly cash pay, with no REMS. Spravato is FDA approved for specific indications, dispensed through a restricted program, and covered by many payers. Those are opposite buying decisions.

Most Spravato centers have a services page that mentions esketamine once and never names the distinction. That page loses to whichever local infusion clinic wrote a real comparison. Written straight, including what Spravato is not good for, the comparison page is usually the page that produces the calls.

It also filters. A patient who reads the two-hour monitoring requirement and the no-driving rule before calling is a patient who shows up for the second dose.

Two hours of chair time is the entire economic model

Capacity is fixed by monitored chairs and staff, and induction dosing is twice weekly for the first four weeks before it steps down. Acquisition is only half the problem. A patient who stops after three doses consumed the intake work and produced almost none of the revenue, and no ad campaign fixes that.

So the marketing has to do two jobs: fill the schedule at a pace the chairs can absorb, and set expectations well enough that patients complete induction. A center at capacity does not need more ads, it needs a referral pattern it can turn up and down.

The best source of an appropriate patient is a psychiatrist who has already run two antidepressant trials and documented them. Consumer search brings volume; prescriber referral brings patients who qualify on the first benefits check.

Spravato Marketing: how we run it for spravato providers

The Spravato versus ketamine page

One page that draws the line clearly: approval status, REMS requirements, monitoring, coverage, and who each option suits. It captures the confused searcher and it disqualifies the wrong ones before they book.

Coverage and prior authorization content

What payers generally require, what the patient pays, how long authorization takes, and what documentation the referring prescriber needs to send. This content answers the question that actually stops people from calling.

Referring prescriber marketing

Direct outreach and materials for psychiatrists, primary care, and therapy practices, including a referral path that does not require the prescriber to learn the REMS. For a certified center this is the most reliable channel.

Local search and the treatment center locator

Google Business Profile per site plus an accurate listing in the manufacturer's treatment center locator, which receives demand from national advertising you did not pay for.

Tracking to first dose and completed induction

Call tracking by campaign and page, handoff into your system, and reporting that ends at patients who started and patients who completed induction rather than at form fills.

Services

What we would run here

Search engine optimization

Other agencies report positions; we report phone calls. Every keyword we chase is one a family types when they are ready to place someone, and every call traces back to the page that earned it.

Local search marketing

Families search for help close to home, and the map pack sits above every organic result on that search. Ranking your locations there is a different job than ranking a website, and for treatment providers it carries rules nobody else deals with.

PPC management

Our best-fit accounts run $50,000 to $100,000 a month through Google. Run right, paid search is the only channel that produces admissions this month; run badly, it funds your competitors' research.

Lead generation

Lead generation in this industry has a bad name for good reasons: the same inquiry sold to four facilities, per-admission deals that violate federal law, dashboards full of form fills nobody answered. We build the opposite — your own inquiry flow, on your own numbers, tracked to the admission.

Call tracking and analytics

Every page, every campaign, and every listing gets its own number. When admissions picks up, we already know what made the phone ring.

Free audit

Want to see where your calls are going?

We audit your rankings, ads, and call tracking against the programs you compete with, then show you what is leaking. Yours to keep either way.

Prefer the phone? (561) 269-2833

Compliance

The rules that apply to this category

This is the part that catches agencies who have not worked in this category before.

The SPRAVATO REMS

Esketamine is available only through a restricted program. The healthcare setting must be certified, the patient must be enrolled, dosing happens on site, and the patient is monitored for at least two hours and cannot drive until the next day after restful sleep. Any copy implying take-home dosing or an at-home option violates the program and the label. The REMS has been modified since launch. current SPRAVATO REMS requirements and monotherapy indication status — verify against the REMS program before publishing

Boxed warning and fair balance

Spravato carries a boxed warning covering sedation, dissociation, abuse and misuse, and suicidal thoughts and behaviors. Manufacturers are bound by promotional labeling rules that require risk information to travel with benefit claims. Providers have more latitude, and the moment you use manufacturer-supplied creative or repeat efficacy language from the label, those rules follow the material onto your site.

Indication limits

The approved indications are treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. Advertising esketamine for anxiety, PTSD, bipolar depression, or chronic pain is off-label promotion of a Schedule III controlled substance. It is also the most common thing we find on a Spravato site during an audit.

Google Ads and prescription drug terms

Google restricts advertising of prescription drugs, and enforcement in this category tends to be a suspension rather than a warning. Campaigns run on condition and service terms, with the brand name handled carefully on the landing page instead of in ad copy. Policy here moves, so we verify before launch rather than after a disapproval.

Sources

FAQ

Questions we get asked

Can we advertise Spravato by name on Google?

Not in the ad copy. Google restricts prescription drug advertising and enforcement here is account level, so campaigns run on condition and service terms such as treatment-resistant depression in your city, and the landing page carries the brand name with the required context. We verify the policy before every launch, because this one moves.

How is this different from marketing a ketamine infusion clinic?

Almost entirely. Spravato is FDA approved for specific indications, dispensed through a restricted REMS program in a certified setting, and covered by many payers. Ketamine infusion is off-label use of a generic drug, usually cash pay, with no REMS. The buying decision, the price, and the compliance rules are different, so the pages have to be different too.

Should we market to patients or to referring psychiatrists?

Prescribers first, patients second. A referred patient already has documented antidepressant trials, which is what authorization requires, so those convert best. Consumer search produces volume and reaches people whose own prescriber has never mentioned esketamine. Most centers we audit are doing neither deliberately.

Our chairs are already full. Is there anything to do?

Then do not buy ads. The work at capacity is retention through induction, a referral pattern you can throttle, and content that pre-qualifies so intake time is not spent on people who do not meet the indication. We will say this on the audit call rather than sell you a campaign you do not need.

Can we put patient testimonials on the site?

Not about the drug's effect. A testimonial about a prescription drug pulls in FTC substantiation rules and, if it repeats an efficacy claim, promotional labeling expectations. Written patient authorization does not remove the risk that the quote reads as an outcome guarantee. We build proof from credentials, the certified-setting standard, and cited clinical literature instead.

Free audit

Find out where your calls are leaking.

We take apart your rankings, your ads, and your call tracking, then show you where the calls are going instead of to you. The audit is yours to keep whether we work together or not.

Prefer the phone? (561) 269-2833